ProCE Banner Activity

EURO-SKI: Defining Cutoffs for Tyrosine Kinase Inhibitor Cessation in Patients With Chronic Myeloid Leukemia

Slideset Download
Conference Coverage
Observational study found that a TKI duration of 5.8 years and MR4 duration of 3.1 years decreased the likelihood of relapse for patients with CML discontinuing TKI therapy.

Released: December 12, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology